Brief: Biomerieux Cuts 2025 Sales Growth Outlook To Max. 6.5%
Nov 4 (Reuters) - Biomerieux SA BIOX.PA: OUTLOOK 2025: SALES ARE NOW EXPECTED TO GROW BETWEEN +5.5% AND +6.5% OUTLOOK 2025: CONFIRMATION OF THE EXPECTED +12% TO +18% GROWTH IN CONTRIBUTIVE OPERATING INCOME BEFORE NON-RECURRING ITEMS (CEBIT) 9M SALES EUR 2,992M MILLION CURRENCY EFFECT EXPECTED TO HAVE NEGATIVE IMPACT IN RANGE OF AROUND - EUR 30M ON 2025 ANNUAL CEBIT Source text Further company coverage: BIOX.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Biomerieux SA
See all newsFactbox: What Bundibugyo Ebola vaccines and treatments are under development
Factbox: What Bundibugyo Ebola vaccines and treatments are under development
Factbox: What Bundibugyo Ebola vaccines and treatments are under development
Factbox: What Bundibugyo Ebola vaccines and treatments are under development
Factbox: What Bundibugyo Ebola vaccines and treatments are under development